Thrombin alfa is a platelet activating factor used to treat minor bleeding. Thrombin Alfa is a human coagulation protein produced via recombinant DNA technology from a genetically modified CHO cell line.
- Mechanism
- Curator reviewed
Specifically, thrombin alfa is a human serine protease that promotes hemostasis and acts locally when applied topically to a site of bleeding. In particular, thrombin alfa activates platelets and cleaves fibrinogen to fibrin, leading directly to clot formation. It also activates clotting factor XIII, leading to fibrin cross-linking and clot stability. The ability of thrombin alfa to bypass the initial enzymatic steps of the coagulation pathway provides a clear rationale as to why thrombin alfa may be used as a topical haemostatic agent.
- Primary indication
- Indicated to aid hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques (such as suture, ligature, or cautery) is ineffective or impractical...Curator reviewed · 1 structured indication
- First approval
- Canada, 2019 · United States, 2008
- Also known as
- Human Thrombin (recombinant, glycosylated) · Thrombin (synthetic human)
- Brand names
Resolves to
What you can answer from here — as of April 23, 2024
Which drugs share a target with Thrombin alfa, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account